Cargando…
Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge
INTRODUCTION: : The impact of vaccination and casirivimab-imdevimab monoclonal antibody treatment on the clinical outcome of COVID-19 during a period of SARS-CoV-2 Delta surge is not known. AIM AND METHODS: : All patients with COVID-19 at our facilities in the US Midwest were enrolled to assess brea...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8574126/ https://www.ncbi.nlm.nih.gov/pubmed/34775142 http://dx.doi.org/10.1016/j.jcv.2021.105026 |